Dr. Michael Murphy

Dr. Murphy’s professional career has spanned 25 years and his positions within the pharmaceutical industry emphasize the integration of medical and scientific acumen with operational excellence. He is board-certified in psychiatry and has a doctorate in pharmacology, with training at Tulane University, Stanford University and the Mt. Sinai School of Medicine.

Dr. Murphy worked with Dr. Cutler in articulating this vision for Worldwide when the company was established as a global CRO in 1995 and was responsible for consulting services for protocol and program design, and executive oversight for the execution, analysis and interpretation of clinical trials across multiple therapeutic areas.

His supervisory responsibilities as Chief Medical & Scientific Officer at Worldwide are international in scope and include the design and implementation of protocol feasibility assessments, protocol development for phases I–IV including non-interventional research, the provision of medical monitoring and drug safety services, medical writing, and coordination of rater certification and surveillance activities for clinical trial assessments.

Prior to joining Worldwide, Dr. Murphy was Chief Medical Officer and Senior Vice President of Discovery and Development at TorreyPines Therapeutics, Inc., with contributions emphasizing translational research in neurodegenerative conditions and analgesia. Dr. Murphy also served as President of the clinical research organization then Chief Medical and Scientific Officer for a large CRO. As President, this CRO was rated “number one” in the United States by CenterWatch.

He has been a consultant for the Duke Clinical Research Institute and is Research and Development Editor for American Health and Drug Benefits™, a publication that focuses upon cost, quality and access in the transition of novel diagnostics and therapeutics from discovery to commercialization.

As a faculty member within the Center for Experimental Pharmacology and Therapeutics at Harvard-MIT Division of Health Sciences and Technology, he has been a lecturer for 15 years within a competitive and credentialed clinical investigator training program.